Patent · US Active

FGL2 antibodies and binding fragments thereof and uses thereof

US11325969B2 · kind B2 · utility

0Cited by

3References

9Claims

0Family size

Assignee

Veritas Therapeutics Inc. · CA

Inventors

Gary Levy · Thornhill, CA
Ramzi Khattar · Toronto, CA
Andrzej Chruscinski · Toronto, CA
Barbara Vanderhyden · Ottawa, CA
Curtis McCloskey · Ottawa, CA

Key dates

Filing date	May 3, 2018
Grant date	May 10, 2022
Priority date	—
Expiry date	May 3, 2038

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The disclosure is directed to antibodies and binding fragments thereof that specifically bind FGL2. The disclosure is also directed to uses of the antibodies and binding fragments thereof for treating cancer.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.